REDDY-EVEROLIMUS 2.5 MG
EVEROLIMUS : 2.5 MG · DIN 02532409 · DR REDDY'S LABORATORIES LTD
Health Canada status: MARKETED
What is REDDY-EVEROLIMUS?
REDDY-EVEROLIMUS 2.5 MG contains EVEROLIMUS : 2.5 MG. It is listed in the Health Canada Drug Product Database under DIN 02532409, held by DR REDDY'S LABORATORIES LTD, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 27-Aug-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is REDDY-EVEROLIMUS used for?
HR+ HER2- advanced breast cancer, pancreatic NET, GI/lung NET, metastatic RCC, renal angiomyolipoma (TSC), and SEGA (TSC).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02532409 |
|---|---|
| Brand name | REDDY-EVEROLIMUS |
| Generic / active ingredient | EVEROLIMUS : 2.5 MG |
| Manufacturer | DR REDDY'S LABORATORIES LTD |
| Strength | 2.5 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | L04AH02 EVEROLIMUS |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 27-Aug-2024 |
| Original market date | 2024-08-27 00:00:00 |
How is it administered?
10 mg once daily for oncology/renal angiomyolipoma. SEGA: starting dose 4.5 mg/m2 daily, titrated to trough levels of 5-15 ng/mL. Administer consistently with or without food.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
(Not explicitly detailed in the provided text snippet; refer to full monograph).
How is it supplied?
Available in 2.5 mg, 5 mg, 7.5 mg, and 10 mg strengths. (Specific container sizes not provided in text).
Contraindications
Hypersensitivity to everolimus, other rapamycin derivatives, or any ingredient in the formulation.
Warnings and precautions
Non-infectious pneumonitis, infections, and renal failure (all potentially fatal). Therapeutic drug monitoring required for SEGA. Not interchangeable with tablets for oral suspension.
What can be used instead?
Other Canadian products sharing ATC code L04AH02 EVEROLIMUS. 21 of 28 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AFINITOR | 10 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02339528 |
| AFINITOR | 2.5 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02369257 |
| AFINITOR | 5 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02339501 |
| AFINITOR DISPERZ | 2 MG | TABLET FOR SUSPENSION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02425645 |
| AFINITOR DISPERZ | 3 MG | TABLET FOR SUSPENSION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02425653 |
| AFINITOR DISPERZ | 5 MG | TABLET FOR SUSPENSION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02425661 |
| NAT-EVEROLIMUS | 10 MG | TABLET | NATCO PHARMA (CANADA) INC | MARKETED | DIN 02530120 |
| NAT-EVEROLIMUS | 2.5 MG | TABLET | NATCO PHARMA (CANADA) INC | MARKETED | DIN 02530090 |
| NAT-EVEROLIMUS | 5 MG | TABLET | NATCO PHARMA (CANADA) INC | MARKETED | DIN 02530104 |
| PMS-EVEROLIMUS | 10 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02504693 |
Who else supplies EVEROLIMUS worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. EVEROLIMUS appears in 433 registered pack listings across 14 markets, published on 12 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.